Palvella Therapeutics (PVLA) Other Non-Current Liabilities (2013 - 2026)

Palvella Therapeutics (PVLA) has 12 years of Other Non-Current Liabilities data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 25.26% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 25.26% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 23.92% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $2.2 million, up from $2.0 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for PVLA reached as high as $2.2 million in Q1 2026 and fell as low as $1.0 million in Q4 2023.
• Historically, Other Non-Current Liabilities has averaged $1.8 million across 4 years, with a median of $1.8 million in 2025.
• Across the five-year window, Other Non-Current Liabilities surged 62.43% in 2024 and increased 23.92% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $1.0 million in 2023, then jumped by 62.43% to $1.6 million in 2024, then advanced by 23.92% to $2.0 million in 2025, then advanced by 5.68% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $2.2 million in Q1 2026, $2.0 million in Q4 2025, and $1.9 million in Q3 2025.